Dr Reddy's Laboratories Net Change in Long-Term Investments 2010-2024 | RDY
Dr Reddy's Laboratories annual/quarterly net change in long-term investments history and growth rate from 2010 to 2024. Net change in long-term investments can be defined as the net cash flows from the sale and purchase of investments with maturities greater than one year.
- Dr Reddy's Laboratories net change in long-term investments for the quarter ending December 31, 2024 was $310M, a 354.1% decline year-over-year.
- Dr Reddy's Laboratories net change in long-term investments for the twelve months ending December 31, 2024 was $237M, a 169.1% decline year-over-year.
- Dr Reddy's Laboratories annual net change in long-term investments for 2024 was $-0.19B, a 33.33% decline from 2023.
- Dr Reddy's Laboratories annual net change in long-term investments for 2023 was $-0.285B, a 92.57% increase from 2022.
- Dr Reddy's Laboratories annual net change in long-term investments for 2022 was $-0.148B, a 364.29% decline from 2021.
Dr Reddy's Laboratories Annual Net Change in Long-Term Investments
(Millions of US $) |
| 2024 |
$-190 |
| 2023 |
$-285 |
| 2022 |
$-148 |
| 2021 |
$56 |
| 2020 |
$-3 |
| 2019 |
$-33 |
| 2018 |
$-67 |
| 2017 |
$337 |
| 2016 |
$16 |
| 2015 |
$-133 |
| 2014 |
$N/A |
| 2013 |
$N/A |
| 2012 |
$N/A |
| 2011 |
$N/A |
| 2010 |
$N/A |
| 2009 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$11.261B |
$3.350B |
|
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
|
